Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

Affiliation auteurs!!!! Error affiliation !!!!
TitrePrognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
Type de publicationJournal Article
Year of Publication2020
AuteursTougeron D, Sueur B, Zaanan A, de la Fouchardiere C, Sefrioui D, Lecomte T, Aparicio T, Guetz GDes, Artru P, Hautefeuille V, Coriat R, Moulin V, Locher C, Touchefeu Y, Lecaille C, Goujon G, Ferru A, Evrard C, Chautard R, Gentilhomme L, Vernerey D, Taieb J, Andre T, Henriques J, Cohen R, Oncologu AGastro-ent
JournalINTERNATIONAL JOURNAL OF CANCER
Volume147
Pagination285-296
Date PublishedJUL 1
Type of ArticleArticle
ISSN0020-7136
Mots-clésChemosensitivity, Colorectal cancer, deficient mismatch repair, metastatic, microsatellite instability
Résumé

{Mismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent about 5% of metastatic CRC (mCRC). Prognosis and chemosensitivity of dMMR/MSI mCRC remain unclear. This multicenter study included consecutive patients with dMMR/MSI mCRC from 2007 to 2017. The primary endpoint was the progression-free survival (PFS) in a population receiving first-line chemotherapy. Associations between chemotherapy regimen and survival were evaluated using a Cox regression model and inverse of probability of treatment weighting (IPTW) methodology in order to limit potential biases. Overall, 342 patients with dMMR/MSI mCRC were included. Median PFS and overall survival (OS) on first-line chemotherapy were 6.0 and 26.3 months, respectively. For second-line chemotherapy, median PFS and OS were 4.4 and 21.6 months. Longer PFS (8.1 vs. 5.4 months
DOI10.1002/ijc.32879